Haifei Xiang

Haifei Xiang


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2024 in Toxicology and Applied Pharmacology
Verified
Journal Article
Closed access
YZYin-Jin Zhang
Yin-Jin Zhang
LCLing-Yang Chen
Ling-Yang Chen
FLFeng Lin
Feng Lin
XZXia Zhang
Xia Zhang
HXHaifei Xiang
Haifei Xiang
QRQing Rao
Qing Rao

27 October 2025 in Annals of Medicine
Verified
Journal Article
Open access
GYGuo Yu
Guo Yu
CZChun-Lian Zhou
Chun-Lian Zhou
MZMin-Shu Zhu
Min-Shu Zhu
RLRui Lu
Rui Lu
JCJun-Ming Chen
Jun-Ming Chen
HXHaifei Xiang
Haifei Xiang
The efficacy of remimazolam compared to propofol for sedation during gynaecologic procedures remains unknown, due to the increased severity of pain associated with these procedures. Therefore, a systematic review and meta-analysis was conducted to address this issue. The protocol has been registered with PROSPERO, number CRD42024511475. Medline/PubMed, Cochrane Library, Embase, Scopus and Web of Science were searched to identify randomized controlled trials (RCTs) covering the period up to 10 January 2025. The primary outcomes comprised the success rate of sedation and the incidence of body movement. Secondary outcomes included recovery time and incidence of adverse effects (i.e. hypotension, bradycardia, respiratory depression, postoperative nausea and vomiting (PONV), dizziness, hiccup and injection pain). Nine RCTs (1129 patients) were included in this meta-analysis. There were no significant differences for the success rate of sedation (RR = 0.98, 95% confidence interval (CI) 0.96-1.00) or the incidence of body movement (RR = 1.03, 95% CI 0.49-2.14). Remimazolam had a lower incidence of adverse effects, including hypotension (RR = 0.21, 95% CI 0.11-0.41), bradycardia (RR = 0.12, 95% CI 0.02-0.97), respiratory depression (RR = 0.30, 95% CI 0.15-0.61), injection pain (RR = 0.06, 95% CI 0.02-0.17) and dizziness (RR = 0.29, 95% CI 0.10-0.82). However, remimazolam increased the incidence of hiccup (RR = 10.16, 95% CI 2.48-41.61). No significant differences were found regarding the recovery time (MD = 1.58, 95% CI -0.20 to 3.35) or the incidence of PONV (RR = 0.68, 95% CI 0.15-3.05). In gynaecologic procedures, remimazolam has comparable efficacy to propofol in the success rate of sedation and the incidence of body movement, while exhibiting superior respiratory and cardiovascular safety profiles. These findings should be cautiously generalized to other populations, and warrant further validation.